Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding increases in their ordinary shareholdings.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change reported is the increase in ordinary share interests for nine specific individuals following the re-investment of dividends paid on April 11, 2013. The shares were purchased at a price of 1,612.44 pence per share on April 16, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investors
- Transaction Type: Dividend re-investment resulting in increased shareholdings for directors and senior management.
- Transaction Date: April 16, 2013.
- Share Price: 1,612.44 pence per share.
- Notable Participants: Includes Dr. M M Slaoui, Mr. S A Hussain, and Dr. P J T Vallance, among others.
- Notification Date: The company was advised of these transactions on April 18, 2013.